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AbsTrACT
background Different diagnostic and classification 
criteria are available for hereditary recurrent fevers (HRF)—
familial Mediterranean fever (FMF), tumour necrosis factor 
receptor-associated periodic fever syndrome (TRaPs), 
mevalonate kinase deficiency (MKD) and cryopyrin-
associated periodic syndromes (CaPs)—and for the 
non-hereditary, periodic fever, aphthosis, pharyngitis and 
adenitis (PFaPa). We aimed to develop and validate new 
evidence-based classification criteria for HRF/PFaPa.
Methods step 1: selection of clinical, laboratory and 
genetic candidate variables; step 2: classification of 360 
random patients from the eurofever Registry by a panel 
of 25 clinicians and 8 geneticists blinded to patients’ 
diagnosis (consensus ≥80%); step 3: statistical analysis for 
the selection of the best candidate classification criteria; 
step 4: nominal group technique consensus conference 
with 33 panellists for the discussion and selection of the 
final classification criteria; step 5: cross-sectional validation 
of the novel criteria.
results The panellists achieved consensus to classify 
281 of 360 (78%) patients (32 CaPs, 36 FMF, 56 MKD, 
37 PFaPa, 39 TRaPs, 81 undefined recurrent fever). 
Consensus was reached for two sets of criteria for each 
HRF, one including genetic and clinical variables, the other 
with clinical variables only, plus new criteria for PFaPa. 
The four HRF criteria demonstrated sensitivity of 0.94–1 
and specificity of 0.95–1; for PFaPa, criteria sensitivity and 
specificity were 0.97 and 0.93, respectively. Validation of 
these criteria in an independent data set of 1018 patients 
shows a high accuracy (from 0.81 to 0.98).
Conclusion eurofever proposes a novel set of validated 
classification criteria for HRF and PFaPa with high 
sensitivity and specificity.
InTroduCTIon
In the last 20 years the discovery of the inflam-
masome and the related genes of the now called 
systemic autoinflammatory diseases (SAIDs) has 
led to a completely new line of research. SAIDs 
are caused by exaggerated activation of the innate 
immune system, in the absence of high-titre auto-
antibodies or antigen-specific T-cells.1 1 Recurrent 
(or periodic) fevers are characterised by inflamma-
tory flares separated by intervals of general overall 
well-being. Some conditions are caused by a genetic 
defect and are collectively referred to as hereditary 
recurrent fever (HRF). Familial Mediterranean 
fever (FMF) is caused by mutations of MEFV2 3; 
mevalonate kinase deficiency (MKD), by mutations 
Key messages
What is already known about this subject?
 ► Hereditary recurrent fever (HRF) syndromes are 
genetic disorders secondary to mutations in 
genes involved in the innate immune response.
 ► A number of classification or diagnostic criteria 
have been developed in the past.
 ► Overall, these criteria lack accuracy and do not 
consider the results of genetic analyses, now 
an essential tool for the accurate diagnosis and 
classification of HRF.
What does this study add?
 ► We developed and validate new evidence-based 
classification criteria for HRF and periodic fever, 
aphthosis, pharyngitis and adenitis, combining 
international expert consensus, statistical 
evaluation of real patients from a large data set 
of patients in the Eurofever Registry.
 ► The new classification criteria combine for the 
first time clinical manifestations with genotype.
How might this impact on clinical practice or 
future developments?
 ► The use of these classification criteria is 
recommended for inclusion of patients in 
translational and clinical studies, but they 
cannot be used as diagnostic criteria.
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of the mevalonate kinase gene (MVK)4 5; tumour necrosis factor 
(TNF) receptor-associated periodic fever syndrome (TRAPS), by 
mutations of type I TNF receptor (TNFSRF1A)6; and cryopy-
rin-associated periodic syndromes (CAPS), by mutations of 
NLRP3.7 8 More common forms of recurrent fever syndromes 
include periodic fever, aphthosis, pharyngitis and adenitis 
(PFAPA) syndrome, which is a multifactorial disorder.9 So far, 
several clinical diagnostic and classification criteria have been 
proposed for HRF10–15 and PFAPA.9 16 Overall, these criteria lack 
accuracy and do not consider the results of genetic analyses, now 
an essential tool for the accurate diagnosis and classification of 
HRF.
This distinction between classification and diagnostic criteria 
is not always clear in clinical practice, and the two terms are 
often (wrongly) used interchangeably.17 Classification criteria 
facilitate accurate identification of diseases for clinical or epide-
miological studies, in this context reliably differentiating one 
autoinflammatory disease from another, but are not designed 
to diagnose that autoinflammatory disease; hence, classification 
criteria make the assumption that important disease mimics (eg, 
chronic infection or malignancy) have already been excluded. 
In contrast, diagnostic criteria are designed to positively rule 
in a specific diagnosis in an individual patient, while excluding 
all conditions with different overlapping disease manifesta-
tions based on derivation and validation in cohorts that include 
important disease mimics. As such, classification criteria cannot 
be used as diagnostic criteria.18 19 The purpose of this study was 
to develop and validate new evidence-based classification criteria 
for HRF and PFAPA, combining international expert consensus 
and statistical evaluation of real patients from a large data set of 
patients in the Eurofever Registry.
MeTHods
A multistep process using consensus formation techniques 
(Delphi and nominal group technique (NGT)) and statistical 
evaluations on real patients was used to develop and test the clas-
sification criteria17 (online supplementary figure 1 and supple-
mentary material), based on a methodological framework used 
successfully in previous studies in rheumatology.20–25
step 1: selection of clinical, laboratory and genetic candidate 
variables
A panel of 162 international adult and paediatric experienced 
clinicians completed successive Delphi questionnaires in order to 
propose and then select and rank the variables (clinical manifes-
tations, genetic analyses, laboratory examinations) from 1 (less 
important) to 10 (most important), for classification of each 
HRF26 and PFAPA.27
step 2: classification of patients from the eurofever registry
After selection (online supplementary figure 2), a random sample 
of 360 patients, 60 patients for each disease (FMF, TRAPS, 
MKD, CAPS, PFAPA and undefined recurrent fevers (uRF)) were 
selected from the Eurofever Registry.28 The inclusion criteria for 
the enrolment in the registry have been previously described28 
(see online supplementary material).
Twenty-five international experienced clinicians/researchers 
and eight geneticists (total of 33 panellists) in the field of SAID 
blinded on patients’ original diagnosis were invited to partic-
ipate in a multiround, secured web process to classify each of 
the 360 patients into one of six mutually exclusive diagnoses.29 
Clinicians and geneticists worked separately in the first steps 
(clinicians blinded to genetic results and geneticists blinded to 
clinical data) and then together to reach consensus ≥80% on all 
classifiable patients.
step 3: statistical analysis for the selection of the best 
candidate classification criteria
The statistical analysis plan (full details in the online supplemen-
tary material) foresaw the following steps:
 ► Evaluation through a univariate logistic regression of the 
relationship between each individual top variable identi-
fied in step 1 and each disease as derived from the panel’s 
classification.
 ► Computer generation of more than 30 000 new candidate 
sets of classification criteria through linear combinations of 
genetic and clinical variables with improper linear model-
ling. Additionally, 11 sets of criteria were derived from the 
literature9–16 or proposed by members of the panel based on 
their expertise.
 ► Identification of the top-performing criteria through ranking 
according to the Akaike information criterion (AIC), with 
best model having the lowest AIC.
step 4: nGT Consensus Conference for the selection of the 
final classification criteria
The Consensus Conference was held in Genoa, Italy, on 18–21 
March 2017. Clinicians and geneticists, who participated in the 
step 2 web consensus classification exercise, attended a meeting. 
The overall goal of the meeting was to decide on the final set of 
criteria, using a combination of statistical and consensus (≥80%) 
formation techniques with the consensus panel classification as 
reference standard.
step 5: cross-sectional validation of the final classification 
criteria
The performance of the final set of classification criteria to 
discriminate patients with the different HRF and PFAPA was 
tested, using the original treating physician patients’ diagnosis 
as reference standard for the cross-sectional validation, postcon-
sensus, in a separate set of 1018 patients selected after random 
computer generation from the Eurofever Registry, which 
contains all variables included in the final set of classification 
criteria.
resulTs
The demographic, clinical, genetic and laboratory features of the 
360 patients randomly selected from the Eurofever Registry are 
provided in table 1 and online supplementary table 1.
A total of 100 different genotypes were reported in the 360 
patients included in the classification process as reported in 
online supplementary table 2.
Nine patients with CAPS and two with TRAPS had no muta-
tions detected using Sanger sequencing; thus, at the time of 
enrolment, somatic mosaicism could not be formally excluded in 
them. Low penetrant or incidental (non-confirmatory) genetic 
findings were also reported in 7 patients with PFAPA and 14 
with uRF (online supplementary table 3).
Classification of patients from the eurofever registry
In the first two rounds, evaluation of clinical data by clinicians 
(blinded to genetic results) resulted in consensus of ≥80% for 
a total of 216 of 360 (60%) patients (figure 1); consensus was 
reached in 51 patients with MKD, 43 with TRAPS, 29 with FMF, 
29 with CAPS, 26 with PFAPA and 38 with uRF. Similarly eval-
uation of demographic and genetic data by geneticists (blinded 
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Table 1 Demographic features of the 360 patients included in the study
FMF
n=60
CAPs
n=60
MKd
n=60
TrAPs
n=60
PFAPA
n=60
urF
n=60
Male 30 (50%) 32 (53%) 26 (43%) 35 (58%) 28 (47%) 28 (47%)
Paediatric/Adults 54/6 33/27 45/15 29/31 59/1 39/21
Age, years, median (range) 10.5 (7.0–15.5) 16.0 (8.9–31.6) 16.2 (9.1–23.0) 21.9 (10.5–41.1) 6.6 (3.8–9.5) 13.5 (8.2–26.4)
Age at disease onset, median (range) 3.4 (1.2–6.4) 3.0 (0.5–11.2) 0.4 (0.2–0.9) 3.4 (0.8–10.6) 1.5 (0.7–3.0) 5.9 (2.0–19.1)
Disease duration, median (range) 5.6 (2.7–10.2) 9.0 (4.6–19.1) 14.2 (7.9–20.8) 13.3 (6.8–23.2) 3.9 (2.3–6.8) 4.8 (3.0–8.2)
Episode duration, median (range) 3.0 (2.0–4.0) 2.0 (0.8–5.0) 5.0 (4.0–7.0) 8.0 (5.0–18.0) 4.0 (3.0–5.0) 4.0 (3.0–7.0)
Number episodes/year, median (range) 12.0 (10.0–20.0) 12.0 (6.0–25.0) 12.0 (10.0–16.0) 6.0 (4.0–12.0) 12.0 (12.0–18.0) 12.0 (5.0–13.0)
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis; 
TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome; uRF, undefined recurrent fevers.
Figure 1 Flow chart of the consensus nominal group technique for classification of patients from the Eurofever Registry. CAPS, cryopyrin-associated 
periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis; 
pts, patients; TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.
to clinical data) in two separate rounds reached consensus on 
319 of 360 (89%) with 278 (77%) patients with 80% consensus 
after the first round. At the end of the two initial rounds, 128 
(36%) patients were concordant between the independent eval-
uation of both the clinicians and the geneticists. At the end of 
the fourth round, consensus was achieved in 281 of 360 (78%) 
as follows: 56 (95%) MKD, 39 (76%) TRAPS, 37 (70%) PFAPA, 
36 (71%) FMF, 32 (63%) CAPS and 81 (85%) uRF (figure 1, 
online supplementary table 4). K (concordance coefficient) 
agreement between the panel reference standard classification 
and the original patient diagnosis by the treating physician was 
0.99 for MKD, 0.87 for TRAPS, 0.86 for CAPS, 0.84 for FMF 
and 0.68 for PFAPA.
statistical analysis for the selection of the best classification 
criteria
The top variables arising from step 1 (see the Methods section) 
were included in a univariate logistic regression analysis using 
the 281 patients for which consensus was achieved by the panel 
as outcome. Clinical variables positively and negatively asso-
ciated with each disease are reported in online supplementary 
table 5 with the related OR and 95% CI. The strategy for the 
classification of the genotypes is described in online supplemen-
tary table 6.
A total of 198 over >30 000 possible new sets of classification 
criteria (available on request; 50 for CAPS, 45 for FMF, 44 for 
TRAPS, 32 for MKD and 22 for PFAPA) were retained, based on 
G
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Table 2 New Eurofever/PRINTO classification criteria for hereditary recurrent fevers and their performance in the 281 patients with consensus
CAPs FMF TrAPs MKd
Presence of a confirmatory NLRP3 
genotype* and at least one among the 
following:
 ► Urticarial rash.
 ► Red eye (conjunctivitis, episcleritis, 
uveitis).
 ► Neurosensorial hearing loss.
OR
Presence of not confirmatory NLRP3 
genotype† and at least two among the 
following:
 ► Urticarial rash.
 ► Red eye (conjunctivitis, episcleritis, 
uveitis).
 ► Neurosensorial hearing loss. 
Presence of confirmatory MEFV 
genotype* and at least one among the 
following:
 ► Duration of episodes 1–3 days.
 ► Arthritis.
 ► Chest pain.
 ► Abdominal pain.
OR
Presence of not confirmatory MEFV 
genotype‡ and at least two among the 
following:
 ► Duration of episodes 1–3 days.
 ► Arthritis.
 ► Chest pain.
 ► Abdominal pain. 
Presence of confirmatory TNFRSF1A genotype* 
and at least one among the following:
 ► Duration of episodes ≥7 days.
 ► Myalgia.
 ► Migratory rash.
 ► Periorbital oedema.
 ► Relatives affected.
OR
Presence of a not confirmatory TNFRSF1A 
genotype† and at least two among the 
following:
 ► Duration of episodes ≥7 days.
 ► Myalgia.
 ► Migratory rash.
 ► Periorbital oedema.
 ► Relatives affected. 
Presence of a confirmatory MVK 
genotype* and at least one among the 
following:
 ► Gastrointestinal symptoms.
 ► Cervical lymphadenitis.
 ► Aphthous stomatitis. 
Sensitivity: 1 Sensitivity: 0.94 Sensitivity: 0.95 Sensitivity: 0.98
Specificity: 1 Specificity: 0.95 Specificity: 0.99 Specificity: 1
Accuracy: 1 Accuracy: 0.98 Accuracy: 0.99 Accuracy: 1
A patient with (1) evidence of elevation of acute phase reactants (ESR or CRP or SAA) in correspondence to the clinical flares and (2) careful consideration of possible 
confounding diseases (neoplasms, infections, autoimmune conditions, other inborn errors of immunity) and a reasonable period of recurrent disease activity (at least 6 months) is 
classified as having hereditary recurrent fever if the criteria are met.
*Pathogenic or likely pathogenic variants (heterozygous in AD diseases, homozygous or in trans (or biallelic) compound heterozygous in AR diseases).
†Variant of uncertain significance (VUS). Benign and likely benign variants should be excluded.
‡In trans compound heterozygous for one pathogenic MEFV variants and one VUS, or biallelic VUS, or heterozygous for one pathogenic MEFV variant. See online supplementary 
table 7 for glossary.
AD, autosomal dominant; AR, autosomal recessive; CAPS, cryopyrin-associated periodic syndromes; CRP, C-reactive protein; ESR, erythocytes sedimentation rate; FMF, familial 
Mediterranean fever; MKD, mevalonate kinase deficiency; MVK, mevalonate kinase; PRINTO, pediatric rheumatology international trial organization; SAA, serum amyloid A; 
TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.
Table 3 Eurofever/PRINTO clinical classification criteria for PFAPA and hereditary recurrent fevers and their performance in the 281 for whom 
consensus was achieved
PFAPA CAPs FMF TrAPs MKd
At least seven out of eight:
Presence
 ► Pharyngotonsillitis.
 ► Duration of episodes, 3–6 
days.
 ► Cervical lymphadenitis.
 ► Periodicity.
Absence
 ► Diarrhoea.
 ► Chest pain.
 ► Skin rash.
 ► Arthritis. 
Presence of at least two of five*:
 ► Urticarial rash.
 ► Cold/Stress-triggered 
episodes.
 ► Sensorineural hearing loss.
 ► Chronic aseptic meningitis.
 ► Skeletal abnormalities 
(epiphysial overgrowth/frontal 
bossing). 
At least six out of nine:
Presence
 ► Eastern Mediterranean 
ethnicity.
 ► Duration of episodes, 1–3 
days.
 ► Chest pain.
 ► Abdominal pain.
 ► Arthritis.
Absence
 ► Aphthous stomatitis.
 ► Urticarial rash.
 ► Maculopapular rash.
 ► Painful lymph nodes. 
Score ≥5 points:
Presence
 ► Fever ≥7 days (2 points).
 ► Fever 5–6 days (1 point).
 ► Migratory rash (1 point).
 ► Periorbital oedema (1 point).
 ► Myalgia (1 point).
 ► Positive family history (1 
point).
Absence
 ► Aphthous stomatitis (1 point).
 ► Pharyngotonsillitis (1 point). 
Presence of at least three of six:
 ► Age at onset <1 years.
 ► Gastrointestinal symptoms.
 ► Painful lymph nodes.
 ► Aphthous stomatitis.
 ► Triggers.
 ► Maculopapular rash. 
Sensitivity: 0.97 Sensitivity: 0.80 Sensitivity: 0.91 Sensitivity: 0.87 Sensitivity: 0.91
Specificity: 0.93 Specificity: 0.91 Specificity: 0.92 Specificity: 0.92 Specificity: 0.82
Accuracy: 0.99 Accuracy: 0.85 Accuracy: 0.97 Accuracy: 0.96 Accuracy: 0.92
*Modified by Kuemmerle-Deschner et al.14 See online supplementary table 6 for glossary. See table 2 for prerequisite criteria.
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis; 
PRINTO, pediatric rheumatology international trial organization; TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.
their AIC, for further evaluation at the Consensus Conference, 
together with 11 criteria from the literature (online supplemen-
tary figure 4).
nGT Consensus Conference for the selection of the final 
classification criteria
The performances of all the criteria chosen by the consensus 
in the 281 patients who reached a consensus are reported in 
tables 2 and 3 (see also glossary in online supplementary table 7).
The first disease discussed was FMF. After multiple voting 
sessions, all three tables of experts, which worked independently 
from each other, showed a complete convergent validity selecting 
the same top definition number 38 (online supplementary figure 
4, session A), including genetic and clinical variables with a posi-
tive association (table 2). After general discussion, a second set 
of criteria based solely on clinical criteria was selected to be used 
as a possible tool for the indication for molecular analysis or as 
classification criteria in case genetic testing is not locally available 
G
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(online supplementary figure 4, session B). To this aim, defini-
tion number 12, including clinical variables with both positive 
and negative association with the disease, was chosen (table 3).
The same approach was followed for the other HRFs (CAPS, 
TRAPS, MKD), leading to the selection of criteria with genetic 
and clinical variables (number 32 for CAPS, number 46 for 
TRAPS, number 37 for MKD) (table 2, online supplementary 
figures 6-8). As per the process to establish FMF criteria, a 
set of purely clinical criteria (ie, without genetic results) was 
also selected for each HRF, namely definitions number 20 and 
number 1 for MKD and TRAPS, respectively (table 3). For 
CAPS classification, the experts reached consensus on a modi-
fied version of recently published criteria.14 The performance 
of the original Kummerle criteria (using two out of six criteria) 
in the context of the present study population displayed 
a good sensitivity (0.91), but a low specificity (0.80).14 
In contrast, when the variable ‘musculoskeletal pain’ was 
excluded, a higher specificity (0.94, with a sensitivity of 0.80) 
was achieved, if two out of five criteria are present (table 3). 
The most severe form of CAPS, chonic infantile neurological 
cutaneous articular (CINCA)/neonatal onset multisystemic 
inflammatory disorder (NOMID), displays a chronic rather 
than a recurrent disease course. Patients with CINCA were not 
included in the validation process described above. However, 
when the new genetic and clinical CAPS criteria were tested in 
a separate set of 70 patients with CAPS with chronic disease 
course enrolled in the Eurofever Registry, the sensitivity was 
100% for the genetic and clinical criteria and 80% for the 
clinical criteria (not shown).
Clinical classification criteria for PFAPA were discussed 
between the 25 clinical panellists distributed in two tables (no 
geneticists). After discussion (online supplementary figure 8), 
definition number 13 (clinical variables with both positive and 
negative association) was chosen (table 3). During the Consensus 
Conference, the panel agreed on a few suggested mandatory 
criteria that should be fulfilled in all the patients before the appli-
cation of the new classification criteria (table 3) with a consensus 
of 100% for point 1 and 96% for point 2.
Globally, convergent validity among the three tables of experts 
was obtained for the genetic and clinical definitions of FMF and 
CAPS, whereas for all the other definitions a partial convergent 
validity (agreement in two out of three tables) was reached, with 
the need for a final plenary voting session (online supplementary 
figures 4-8 and online supplementary table 8).
Cross-validation of the final classification criteria
The ability of the new classification criteria to discriminate 
among the different recurrent fevers and uFR was further 
tested in the validation data set of 1018 patients extracted 
from the Eurofever Registry (online supplementary table 9) 
using as reference standard for each patient the diagnosis 
given by the treating physician. In the last column of table 4, 
the genotype (score 0=negative/not done; score 1=not confir-
matory; score 2=confirmatory) of patients not identified by 
the clinical criteria for HRF is reported. Notably, almost all 
the patients not classified by the clinical and genetic criteria 
displayed a negative or not confirmatory genotype (table 4). 
The performance of the new classification criteria (either 
clinical and genetic or clinical only) was generally superior 
(accuracy ranging from 0.81 to 0.98; table 4) to those already 
available in the literature (accuracy 0.56–0.94) (online supple-
mentary table 10).
dIsCussIon
The present study provides new evidence-based classification 
criteria for the four ‘classical’ HRF (FMF, MKD, TRAPS, CAPS) 
and PFAPA, incorporating combined consensus expertise of clini-
cians and geneticists with statistical analyses in real patients from 
the Eurofever Registry. At variance with past work15 these new 
classification criteria combine genetic and clinical variables to 
overcome the paradox of the absence of a role of the molecular 
analysis for the proper identification of patients affected by these 
(mainly) genetic conditions. As defined by the American College 
of Rheumatology, the proposed classification criteria have 
selected clinical and genetic findings able to identify the defined 
diseases and separate from other confounding autoinflammatory 
conditions.18 19 Although these criteria may at times be helpful in 
clinical practice, they are explicitly not meant to be employed as 
diagnostic criteria. The advent of the so-called next-generation 
sequencing era resulted on one side to an increased availability 
of the molecular analysis at reduced costs but might often lead 
to difficulties in the proper interpretation of this large set of 
bioinformatic data. In fact, besides the identification of clearly 
pathogenic variants, in many circumstances (ie, low penetrance 
variants or variants of unknown significance, monoallelic vari-
ants in autosomal recessive diseases, presence of variants in 
more than one gene) the genetic results are not unequivocal and 
should be placed in the context of a pertinent clinical setting. In 
these latter cases, the classification of the patient is usually prob-
lematic, as clearly shown in the process of patients’ validation 
in this study. For these reasons, the panel decided to introduce 
a distinction between a confirmatory (namely, surely or likely 
pathogenic variants) and not confirmatory (variants of unknown 
significance) genetic test. For the daily use of the new criteria, 
a parallel consensus classification effort by the genetic subcom-
mittee of the INSAID project has established the pathogenicity 
of each currently known variant associated to HRF.30 A differen-
tial approach for the interpretation of the biallelic variants was 
chosen for the two autosomal recessive diseases, namely MKD 
and FMF. MKD is caused by loss-of-function mutations in the 
MVK gene. The panel excluded the possibility of classifying a 
patient as an MKD in the absence of biallelic mutations of the 
MVK gene. Conversely, recent evidence has clarified that FMF 
is secondary to gain-of-function mutations of the MEFV gene, 
with a clear dose effect,31 32 and therefore FMF could be clas-
sified with identification of either one or two pathogenic vari-
ants in exon 10 of MEFV in the presence of a consistent clinical 
phenotype. The same possibility was also considered for the 
two autosomal dominant diseases, CAPS and TRAPS, in the 
absence of confirmatory phenotype. In patients carrying vari-
ants of unknown pathogenic significance (such as R92Q and 
P46L for TNFRSF1A, or V198M for NLRP3),33–36 only the pres-
ence of some very specific clinical variables would support the 
proper disease classification. In parallel with the elaboration of 
the definitive criteria that include genetic/clinical variables, the 
panel agreed on additional clinical criteria that should be used 
to (1) identify patients with recurrent fevers that would need to 
undergo genetic testing for molecular confirmation; (2) search 
for possible somatic mosaicism using NG in patients with a clear 
phenotype, but negative Sanger sequencing results; and (3) clas-
sify patients (eg, for epidemiological studies) even in those coun-
tries where routine genetic testing is not possible. For PFAPA, the 
contemporary evaluation of either positive (presence) and nega-
tive (absence) clinical variables yielded a much higher accuracy 
when compared with the classical modified Marshall’s criteria.16 
Following the consensus meeting, the new sets of criteria were 
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further validated in a large group of additional patients from 
the Eurofever Registry, showing a very high specificity when 
compared with previous literature criteria. As noticed, most of 
the diagnoses refuted by the new criteria had been in patients 
with either non-confirmatory or negative genetic tests results. 
It is therefore conceivable that the present new criteria will be 
more stringent in the classification of patients, by excluding a 
substantial proportion of patients carrying variants of unknown 
origin. The classification criteria we propose are accurate for the 
discrimination of one form of autoinflammation from another 
in the context of the six conditions considered herein, but very 
much have to be applied judiciously, after careful consideration 
of confounding diseases, as highlighted in table 2. These classifi-
cation criteria are therefore intended for use for clinical, epide-
miological or translational studies, but not for routine diagnostic 
purposes in individual patients.37 That said, the purely clinical 
classification criteria might guide molecular testing approaches 
for individual cases, although this point requires future valida-
tion. One possible limitation of the present study is the lack of 
comparison groups including possible confounding conditions 
(chronic infections, neoplasms, immune deficiencies, autoim-
mune disease and metabolic diseases) presenting sometimes with 
a recurrent disease course. In daily practice confounding diseases 
with a true recurrent disease course are rather infrequent 
outside HRF and PFAPA, while the most challenging group of 
confounding conditions are the large emerging group of patients 
with uRF, many of whom may have a true monogenetic cause 
other than the four genetic diseases considered herein. For these 
reasons, the different HRFs have been used as controls for each 
individual condition with PFAPA and uRF as genetically nega-
tive controls. The panel of experts unanimously decided that 
the presence of elevation of acute phase reactants during disease 
flares (recorded at least in one occasion) should be considered as 
mandatory preliminary criterion for the use of the new classifi-
cation criteria.14 Some other relevant pathognomonic laboratory 
examinations, such as urinary mevalonic acid in MKD, were not 
available in the Eurofever Registry, probably reflecting the fact 
that it is not widely available for testing routinely. As such the 
panel recommended the importance for the diagnostic work-
up, for example, with intracellular MVK enzyme activity and/
or urinary mevalonic acid in MKD,38 particularly for patients 
with convincing phenotypes but non-confirmatory genotype 
for MKD. Similarly, the response to some specific treatments 
(such as colchicine in FMF or anti-interleukin (IL)-1 in CAPS) 
or ethnic background (for FMF) could certainly be considered as 
additional elements to be considered in daily practice, especially 
for patients with non-confirmatory genotype, but are not good 
discriminators of the different forms of autoinflammatory disease 
considered herein. In conclusion, the present work allowed the 
proposal of novel evidence-based classification criteria for HRF 
and PFAPA with a high specificity. The use of these classifica-
tion criteria is highly recommended for inclusion of patients in 
translational and clinical studies, including clinical trials, and 
should not be misused as diagnostic criteria.17 The possible iden-
tification of new genetic entities in the heterogeneous group of 
undefined periodic fevers could require an update of the criteria 
in the future.
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